MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

0.1888
+0.0088
+4.89%
After Hours: 0.1888 0 0.00% 17:56 04/03 EDT
OPEN
0.1945
PREV CLOSE
0.1800
HIGH
0.1945
LOW
0.1800
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
0.6000
52 WEEK LOW
0.1685
MARKET CAP
31.00M
P/E (TTM)
-1.0661
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATNM stock price target is 2.750 with a high estimate of 4.000 and a low estimate of 1.500.

EPS

ATNM News

More
  • Actinium Treats First Patient in AML Study on Actimab-A Combo
  • Zacks · 03/06 15:56
  • Actinium Pharma up 24% on advancement of Actimab-A in AML
  • Seeking Alpha - Article · 03/05 16:17
  • Actinium Pharma Reports First Patient Treated In Third, Final Dose Cohort Of Actimab-A CLAG-M Combo Phase 1 Trial In ACute Myeloid Leukemia
  • Benzinga · 03/05 12:40
  • Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia
  • PR Newswire · 03/05 12:30

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About ATNM

Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.
More

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.